Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Expired warrants

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Mar 01, 2022 9:46am

158 Views

Post# 34470690

RE:RE:RE:RE:RE:Expired warrants

themagicbox wrote: Hey Mugs how long has this "Chianchin" been following you? His amateur hour comments seem so basic that I am getting the impression he's here to troll you.

Don't know if you remember, LookingforClues trolling here in the past. Ended up in the penalty box. Same guy but he's using the name he created while in the box.

Guess he wants to preserve the old name from the box again.

As nuts as ever ... hahaha !

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China